Inhibition of angiogenesis for the treatment of metastatic melanoma

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Metastatic malignant melanoma is a uniformly fatal disease. Tumor growth and metastasis are associated with angiogenesis and lymphangiogenesis. Proangiogenic factors are associated with higher disease burdens and worse outcomes in melanoma. Accordingly, many agents that target angiogenesis have been studied in melanoma. Angiogenesis is a complex, multifaceted process with many potential therapeutic targets. So far, monoclonal antibodies, immune conjugates, tyrosine kinase inhibitors, immunomodulatory agents, and other therapies have been tested in the phase 2 or phase 3 setting for the treatment of metastatic melanoma. The antiangiogenic agents that have been tested to date offer little activity as single agents, but in combination with cytotoxic agents prolong progression-free survival. We explore data from published phase 2 and phase 3 trials in addition to the purported mechanisms of action of antiangiogenic agents.

Original languageEnglish (US)
Pages (from-to)492-499
Number of pages8
JournalCurrent oncology reports
Issue number5
StatePublished - Oct 2013


  • Angiogenesis
  • Bevacizumab
  • Metastatic Melanoma
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Inhibition of angiogenesis for the treatment of metastatic melanoma'. Together they form a unique fingerprint.

Cite this